文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺癌VMAT自动遗传规划的多中心验证

Automatic genetic planning for volumetric modulated arc therapy: A large multi-centre validation for prostate cancer.
PubMed 文献 · Radiother Oncol · 2020-04-21

在10家放疗中心对100例前列腺癌患者验证首个临床遗传自动规划算法GPS,与人工规划比较剂量学参数和临床盲评分。GPS仅用单中心数据调参后直接应用于所有中心,91%计划临床可接受,OAR剂量显著降低,69%可接受自动计划优于人工计划。

要点

  • GPS仅用单中心数据调参即可在多中心生成临床可接受的前列腺癌VMAT计划。
  • 自动计划OAR剂量显著低于人工计划,直肠Dmean降低17.9%、膀胱Dmean降低10.3%。
  • 临床盲评中69%可接受自动计划优于对应人工计划,偏好人工计划的优势较小。

核心结论

  • 遗传自动规划算法GPS无需中心特异性调参即可在不同中心生成高质量前列腺癌VMAT计划。

研究设计与样本

  • 在10家放疗中心对共100例前列腺癌患者比较GPS自动计划与人工计划,GPS仅用单中心数据调参后直接应用。
  • 每中心10例,比较剂量学参数和临床盲评分,自动计划未做患者特异性微调。

主要发现

  • 9家中心全部10例计划临床可接受,剩余1家中心仅1例可接受。
  • 91%可接受计划中靶区覆盖差异可忽略,OAR剂量在自动计划中显著更低(p < 0.05)。
  • 直肠D15%和Dmean分别降低8.1%和17.9%,膀胱D25%和Dmean分别降低5.9%和10.3%。
  • 临床医生认为69%可接受自动计划优于对应人工计划;偏好人工计划的31%中感知优势较小。
  • QA测量表明自动计划可执行;不可接受计划的中心快速调整配置后100%计划可接受。

临床怎么用

  • 前列腺癌VMAT可采用GPS自动规划生成临床可接受计划,减少对中心特异性调参的依赖。
  • 自动计划OAR剂量更低,多数计划临床盲评优于人工计划,可辅助提升计划质量。
  • 对于计划不可接受的中心,快速配置调整可显著提高可接受率。

局限性

  • 研究仅针对前列腺癌VMAT,结论外推至其他瘤种或技术需进一步验证。
  • 单中心调参后直接应用,未评估患者特异性微调的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The first clinical genetic autoplanning algorithm (Genetic Planning Solution, GPS) was validated in ten radiotherapy centres for prostate cancer VMAT by comparison with manual planning (Manual). METHODS: Although there were large differences among centres in planning protocol, GPS was tuned with the data of a single centre and then applied everywhere without any centre-specific fine-tuning. For each centre, ten Manual plans were compared with autoGPS plans, considering dosimetric plan parameters and the Clinical Blind Score (CBS) resulting from blind clinician plan comparisons. AutoGPS plans were used as is, i.e. there was no patient-specific fine-tuning. RESULTS: For nine centres, all ten plans were clinically acceptable. In the remaining centre, only one plan was acceptable. For the 91% acceptable plans, differences between Manual and AutoGPS in target coverage were negligible. OAR doses were significantly lower in AutoGPS plans (p < 0.05); rectum D15% and Dmean were reduced by 8.1% and 17.9%, bladder D25% and Dmean by 5.9% and 10.3%. According to clinicians, 69% of the acceptable AutoGPS plans were superior to the corresponding Manual plan. In case of preferred Manual plans (31%), perceived advantages compared to autoGPS were minor. QA measurements demonstrated that autoGPS plans were deliverable. A quick configuration adjustment in the centre with unacceptable plans rendered 100% of plans acceptable. CONCLUSION: A novel, clinically applied genetic autoplanning algorithm was validated in 10 centres for in total 100 prostate cancer patients. High quality plans could be generated at different centres without centre-specific algorithm tuning.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Fiandra C, Rossi L, Alparone A, et al. Automatic genetic planning for volumetric modulated arc therapy: A large multi-centre validation for prostate cancer. Radiother Oncol. 2020. PMID: 32361572. doi:10.1016/j.radonc.2020.04.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。